Efficacy of Omalizumab in Mastocytosis: Allusive Indication Obtained from a Prospective, Double-Blind, Multicenter Study (XOLMA Study).

Abstract

BACKGROUND:

Patients with mastocytosis often suffer from a variety of symptoms caused by mast cell mediators where treatments remain difficult, showing various success rates. Omalizumab, a monoclonal anti-IgE antibody, has been postulated to have a positive impact on mastocytosis-associated symptoms such as flush, vertigo, gastrointestinal problems, or anaphylaxis.

OBJECTIVE:

To investigate the efficacy and safety of omalizumab in systemic mastocytosis.

METHODS:

Patients with histologically proven mastocytosis were investigated in a multicenter prospective double-blind placebo-controlled trial to receive either omalizumab or placebo, dosed according to IgE and body weight. The primary endpoint was change in the AFIRMM activity score after 6 months of treatment. Different laboratory parameters were analyzed.

RESULTS:

Sixteen patients were analyzed: 7 to omalizumab and 9 to placebo (mean age 47.7 ± 13.8 vs. 45.4 ± 8.8 years; 66.6 vs. 85.7% were female; mean disease duration 10.0 ± 5.1 vs. 4.5 ± 2.9 years, respectively). After 6 months the median AFIRMM score decreased 50% from 52.0 to 26.0 in the omalizumab group versus 104.0-102.0 in the placebo group (p = 0.286); however, the difference was not significant (p = 0.941). Secondary endpoints, including the number of allergic reactions, changes in major complaints, wheal-and-flare reaction due to mechanical irritation (Darier's sign), and frequency of the use of mastocytosis-specific drugs improved in the omalizumab group, but not significantly. Adverse events like urticaria, bronchospasm, and anaphylactic shock showed no significant difference between the groups. No severe adverse events occurred. FcεRI (Fc-epsilon receptor) expression on basophils decreased after receiving omalizumab versus placebo.

CONCLUSION:

Omalizumab was safe and showed a tendency to improve mastocytosis-related symptoms, in particular diarrhea, dizziness, flush, and anaphylactic reactions, including the AFIRMM score and secondary endpoints; however, the difference was not significant. Due to the small study size and difference at baseline between the study groups, further studies are required to confirm our findings.

• Authors: Meike Distler, Julia-Tatjana Maul, Urs C Steiner, Peter Jandus, Antonios G A Kolios, Carla Murer, Nicole Graf, Jörg D Seebach, Werner J Pichler, Alexander A Navarini, Lars E French, Arthur Helbling, Peter Schmid-Grendelmeier
• Journal: Dermatology (Basel, Switzerland) (Dermatology) Vol. 236 Issue 6 Pg. 529-539 ( 2020) ISSN: 1421-9832 [Electronic] Switzerland
• PMID: 31958790 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
• Copyright: © 2020 S. Karger AG, Basel.

Chemical References

• Anti-Allergic Agents
• Omalizumab

Topics

• Adult
• Anti-Allergic Agents (therapeutic use)
• Double-Blind Method
• Female
• Humans
• Male
• Mastocytosis (drug therapy)
• Mastocytosis, Systemic (drug therapy)
• Middle Aged
• Omalizumab (therapeutic use)
• Prospective Studies